Cancer Research and Treatment

The Korean Cancer Association (대한암학회)
권호 표지

Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer

Ko, Yoon-Ho;Jung, Chan-Kwon;Lee, Myung-Ah;Byun, Jae-Ho;Kang, Jin-Hyoung;Lee, Kyo-Young;Jo, Keon-Hyun;Wang, Young-Pil;Hong, Young-Seon

  • Published : 2008.11.30
⟨ Previous Next ⟩

Abstract

Purpose: Lymphatic spread of tumor is an important prognostic factor for patients with non-small cell lung carcinoma (NSCLC). Vascular endothelial growth factor-C (VEGF-C) and VEGF-D play important roles in lymphangiogenesis via the VEGF receptor 3 (VEGFR-3). We sought to determine whether VEGF-C, VEGF-D and VEGFR-3 are involved in the clinical outcomes of patients with resected NSCLC. Materials and Methods: Using immunohistochemical staining, we investigated the protein expressions of VEGF-C, VEGF-D and VEGFR-3 in the tissue array specimens from patients who underwent resection for NSCLC. The immunoreactivity for p53 was also examined. The clinicopathological implications of these molecules were statistically analyzed. Results: Analysis of a total of 118 specimens showed that VEGF-C, VEGF-D and their co-expression were significantly associated with more advanced regional lymph node metastasis (p=0.019, p=0.044 and p=0.026, respectively, N2 versus N0 and N1). A VEGFR-3 expression had a strong correlation with peritumoral lymphatic invasion (p=0.047). On the multivariate analysis for survival and recurrence, pathologic N2 lymph node metastasis was the only independent prognostic factor, but none of the investigated molecules showed any statistical correlation with recurrence and survival. Conclusions: The present study revealed that high expressions of VEGF-C and VEGF-D were strongly associated with more advanced regional lymph node metastasis in patients with resected NSCLC.

Keywords

References

  1. Park K. Second-line chemotherapy for advanced non-small cell lung cancer: past, present, and hope for the future. Cancer Res Treat. 2003;35:279-80 https://doi.org/10.4143/crt.2003.35.4.279
  2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-7 https://doi.org/10.1378/chest.111.6.1710
  3. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Yokose T, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer. 1999;86:1976- 84 https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<1976::AID-CNCR14>3.0.CO;2-I
  4. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573-83 https://doi.org/10.1038/nrc863
  5. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002;62:1669-75
  6. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 2003;88:237-44 https://doi.org/10.1038/sj.bjc.6600701
  7. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24:228-40 https://doi.org/10.1200/JCO.2004.00.3467
  8. Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res. 2005;25:3003-9
  9. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381-90 https://doi.org/10.1016/S0002-9440(10)65392-8
  10. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003;97:457-64 https://doi.org/10.1002/cncr.11073
  11. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203-12
  12. Shaulsky G, Goldfinger N, Rotter V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res. 1991;51:5232-7
  13. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004;64:9027- 34 https://doi.org/10.1158/0008-5472.CAN-04-3703
  14. Mylona E, Alexandrou P, Mpakali A, Giannopoulou I, Liapis G, Markaki S, et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol. 2007;33:294-300 https://doi.org/10.1016/j.ejso.2006.10.015
  15. Adachi Y, Nakamura H, Kitamura Y, Taniguchi Y, Araki K, Shomori K, et al. Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with antipodoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases. Pathol Int. 2007;57:171-7 https://doi.org/10.1111/j.1440-1827.2007.02077.x
  16. Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie. 2005;28:281-8 https://doi.org/10.1159/000085198
  17. Yonemura Y, Endo Y, Tabata K, Kawamura T, Yun HY, Bandou E, et al. Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol. 2005;10: 318-27 https://doi.org/10.1007/s10147-005-0508-7
  18. Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate. 2005;65:110-6 https://doi.org/10.1002/pros.20276
  19. Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 2004;45: 325-37 https://doi.org/10.1016/j.lungcan.2004.02.021
  20. Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T, Strittmatter K, et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol. 2007;170:1348-61 https://doi.org/10.2353/ajpath.2007.060835
  21. Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Onitsuka T. Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value. Respirology. 2005;10:31-5 https://doi.org/10.1111/j.1440-1843.2005.00655.x
  22. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33:125-32 https://doi.org/10.1016/S0169-5002(01)00195-7
  23. Tsubochi H, Sato N, Hiyama M, Kaimori M, Endo S, Sohara Y, et al. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann Thorac Surg. 2006;82:1198-204 https://doi.org/10.1016/j.athoracsur.2006.04.069
  24. Katsuta M, Miyashita M, Makino H, Nomura T, Shinji S, Yamashita K, et al. Correlation of hypoxia inducible factor- 1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol. 2005;78:123-30 https://doi.org/10.1016/j.yexmp.2004.11.002
  25. Longatto Filho A, Martins A, Costa SM, Schmitt FC. VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract. 2005;201:93-9 https://doi.org/10.1016/j.prp.2004.11.008